Ipamorelin Research

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. Published research has investigated it for its selective interaction with the GHS-R1a receptor in the context of growth hormone signaling. Novo Nordisk developed it as a drug candidate, and Raun et al. concluded that its specificity made it a very interesting candidate for future clinical development. Studies noted a more selective endocrine signaling profile than earlier GHRPs such as GHRP-6. Preclinical studies have examined dose-dependent growth hormone secretion patterns in animal models. Research on Ipamorelin has proven important for investigating growth hormone (GH) regulation, given its specific design.

This article explains the Ipamorelin peptide structure and its mechanism of action. It also covers what makes it a selective secretagogue compared with older GHRPs such as GHRP-6, and what the preclinical literature actually shows. Ipamorelin is a research compound and is not characterized for human use here.

Ipamorelin is a selective secretagogue

Ipamorelin is a small synthetic peptide, and its position in the field can best be understood when compared to the previous compounds. Growth hormone-releasing peptides were first described by Bowers et al. in 1980 (Endocrinology 106(3):663-7; PubMed PMID: 7353536). Their 1984 publication reported that a new synthetic hexapeptide, called GHRP-6, could release GH from the pituitary gland.^[1] It did so via an unidentified mechanism independent of GHRH.

GHRP-6 was potent but not a clean probe of the GH axis. Bowers et al. reported GH release without any concomitant rise in LH, FSH, TSH or PRL. They did not report ACTH or cortisol. Later work in conscious swine showed that GHRP-6 also raised plasma ACTH and cortisol (Raun et al.).^[2]

Ipamorelin was identified in a chemistry program screening compounds that lacked the central Ala-Trp dipeptide of GHRP-1. Its failure to raise ACTH and cortisol was an unexpected finding rather than a designed outcome. According to Raun et al.'s 1998 work, it was nonetheless the first example of a selective growth hormone secretagogue of this kind.^[2]

Ipamorelin peptide structure

The Ipamorelin peptide structure is a pentapeptide, written as Aib-His-D-2-Nal-D-Phe-Lys-NH2. Aib is the non-natural residue alpha-aminoisobutyric acid, and D-2-Nal is a D-configuration naphthylalanine. The use of non-natural and D-amino acids, together with the C-terminal amide, is what gives the molecule its metabolic stability.

Its endocrine selectivity is not explained by binding a different receptor. Antagonist profiling by Raun et al. showed that ipamorelin, like GHRP-6, releases GH via the same GHRP-like receptor.^[2] Those authors described the absence of an ACTH and cortisol response as very surprising rather than designed. It is a fully synthetic construct that does not correspond to any natural peptide sequence.

Ipamorelin mechanism of action

The mode of action of Ipamorelin involves a distinct pathway and receptor compared to the GHRH receptor. This receptor, the GHS-R1a, was first discovered by Howard et al. in 1996.^[3] It was found to function as a pituitary and hypothalamic receptor in regulating growth hormone release, though its endogenous ligand had not yet been identified.

It was not until 1999 that Kojima et al. discovered ghrelin, the acylated peptide.^[4] That discovery led to the identification of GHS-R1a as the ghrelin receptor, thereby classifying the GHRPs as ghrelin agonists or analogs.

Ipamorelin binds GHS-R1a receptors in the somatotrophs of the pituitary gland, where it acts to induce GH secretion by activating the signal transduction pathways. It does so without using the cAMP-dependent mechanism employed by GHRH-class secretagogues. As both pathways are distinct yet interconnected, the two types of secretagogues are often studied together.

What makes Ipamorelin more selective than GHRP-6

This is the heart of the Ipamorelin versus GHRP-6 comparison. In the same studies that established its GH-releasing potency, Raun et al. showed that Ipamorelin released GH with potency and efficacy comparable to GHRP-6.^[2] Those same authors reported that in conscious swine, both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while ipamorelin produced ACTH and cortisol levels not significantly different from those following GHRH stimulation. That held even at doses more than 200-fold above its ED50 for GH release.

This is precisely what has made this compound selective. It acts on the GH axis via GHS-R1a, without the ACTH and cortisol rise that GHRP-6 and GHRP-2 produced in the same study. In that study none of the secretagogues tested, ipamorelin included, altered FSH, LH, PRL or TSH. For anyone studying GH biology, a probe that moves GH without simultaneously moving cortisol is a cleaner instrument. That selectivity is the single most cited feature of the molecule.

What the preclinical research shows

The Ipamorelin preclinical studies are where the body of evidence sits. The foundational animal pharmacology study by Raun et al. characterized GH release in rat pituitary cells in vitro, in anesthetized rats and in conscious swine.^[2] The hormone-specificity work that defines the compound, including the ACTH and cortisol measurements, was carried out only in the swine.

In addition to being studied for its fundamental characteristics, the peptide has served as a research tool in specific physiological models. Andersen et al. reported in 2001 that in adult rats, Ipamorelin counteracted a glucocorticoid-induced decrease in bone formation.^[5] That study examined the GH axis in the context of corticosteroid effects on bone.

Separately, Venkova et al. used Ipamorelin as a ghrelin mimetic in a rat model of postoperative ileus in 2009.^[6] They reported that a single dose shortened the time to first bowel movement. That single dose did not change cumulative fecal output, food intake, or weight gain, while repeated dosing increased all three.

Together, these illustrate how the molecule has been deployed across distinct preclinical questions, all in animal or cellular systems. None predicts an outcome in people.

Human research on Ipamorelin

Human research on Ipamorelin is minimal and should be read as separate from the animal work. Two studies in humans have been published. An early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers characterized how the peptide behaves in the body. It also characterized its GH response across five infusion rates (Gobburu et al., Pharm Res 1999; PubMed PMID: 10496658).

Ipamorelin was then taken into clinical development for postoperative ileus, in a phase 2, multicenter, randomized, double-blind, placebo-controlled trial (NCT00672074) in 114 bowel-resection patients. It found the peptide well tolerated but no better than placebo on the key efficacy endpoint. That endpoint was median time to tolerating a standardized solid meal (25.3 h vs 32.6 h, p = 0.15). It was also no better than placebo on the secondary efficacy analyses (Beck et al., Int J Colorectal Dis 2014;29(12):1527-34; PubMed PMID: 25331030).

There is no approved use, and almost everything else known about the compound comes from preclinical pharmacology. Any extrapolation from this limited human data to a real-world outcome is unsupported.

Current limitations and open questions

Studies on Ipamorelin have several limitations to consider when interpreting the results. There is no approved use, and the compound is not characterized for human use. Much of the defining preclinical work comes from the original developer, which raises the usual question of independent replication. The long-term effects of GHS-R1a receptor stimulation are not well characterized.

As with any research peptide, the identity and purity of the material vary across sources, which matters for any laboratory study using research-grade Ipamorelin.

Taking all this into account, the mechanism is well defined and the selectivity is its genuine distinction, though it rests on that single unreplicated developer study. The broader evidence base remains limited, and the open questions are mostly those that properly controlled studies have not yet answered.

Conclusion

Ipamorelin is a selective, synthetic ghrelin receptor agonist: a stable pentapeptide that acts at GHS-R1a to release growth hormone. It spares the ACTH and cortisol responses that complicated earlier GHRPs such as GHRP-6.

The preclinical pharmacology that defines it is coherent, but its selectivity rests on a single set of swine experiments from the original developer. That finding has not been independently replicated. The broader evidence base is limited, with no approved indication.

The findings describe what has been studied in preclinical systems, not what any individual should expect.

References

1. 1

   Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984 May;114(5):1537-45. doi:10.1210/endo-114-5-1537. PMID 6714155. .
2. 2

   Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi:10.1530/eje.0.1390552. PMID 9849822. .
3. 3

   Howard AD, Feighner SD, Cully DF. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. doi:10.1126/science.273.5277.974. PMID 8688086. .
4. 4

   Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. doi:10.1038/45230. PMID 10604470. .
5. 5

   Andersen NB, Malmlof K, Johansen PB, Andreassen TT, Ortoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72. doi:10.1054/ghir.2001.0239. PMID 11735244. .
6. 6

   Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6. doi:10.1124/jpet.108.149211. PMID 19289567. .